Technical Analysis for OCUL - Ocular Therapeutix, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical OCUL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Jan 18 | BB Squeeze Started | Range Contraction | 0.00% |
| Jan 18 | Down 3 Days in a Row | Weakness | 0.00% |
| Jan 16 | Spinning Top | Other | -0.51% |
| Jan 15 | Narrow Range Bar | Range Contraction | -1.25% |
| Jan 15 | NR7 | Range Contraction | -1.25% |
| Jan 14 | Inside Day | Range Contraction | 0.00% |
| Jan 14 | Wide Bands | Range Expansion | 0.00% |
| Jan 14 | Down 3 Days in a Row | Weakness | 0.00% |
| Jan 11 | Wide Bands | Range Expansion | -0.25% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-07
- Sector: Healthcare
- Industry: Medical Equipment, Supplies & Distribution
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more OCUL news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 8.28 |
| 52 Week Low | 3.55 |
| Average Volume | 590,738 |
| 200-Day Moving Average | 6.0769 |
| 50-Day Moving Average | 4.9264 |
| 20-Day Moving Average | 4.0755 |
| 10-Day Moving Average | 4.019 |
| Average True Range | 0.3146 |
| ADX | 32.99 |
| +DI | 10.8899 |
| -DI | 22.6425 |
| Chandelier Exit (Long, 3 ATRs ) | 4.2862 |
| Chandelier Exit (Short, 3 ATRs ) | 4.4938 |
| Upper Bollinger Band | 4.3611 |
| Lower Bollinger Band | 3.7899 |
| Percent B (%b) | 0.26 |
| BandWidth | 14.015458 |
| MACD Line | -0.2965 |
| MACD Signal Line | -0.3303 |
| MACD Histogram | 0.0338 |
| Fundamentals | Value |
|---|---|
| Market Cap | 114.48 Million |
| Num Shares | 29.1 Million |
| EPS | -2.15 |
| Price-to-Earnings (P/E) Ratio | -1.83 |
| Price-to-Sales | 88.04 |
| Price-to-Book | 3.48 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.20 | ||||
| Resistance 3 (R3) | 4.19 | 4.11 | 4.15 | ||
| Resistance 2 (R2) | 4.11 | 4.04 | 4.11 | 4.14 | |
| Resistance 1 (R1) | 4.02 | 4.00 | 3.98 | 4.03 | 4.12 |
| Pivot Point | 3.94 | 3.94 | 3.92 | 3.94 | 3.94 |
| Support 1 (S1) | 3.85 | 3.87 | 3.81 | 3.86 | 3.76 |
| Support 2 (S2) | 3.77 | 3.83 | 3.77 | 3.74 | |
| Support 3 (S3) | 3.68 | 3.77 | 3.73 | ||
| Support 4 (S4) | 3.69 |
